CSPC Pharmaceutical Group (HKG:1093) said its cervical cancer drug received a Fast Track designation by the US Food and Drug Administration, according to a Wednesday filing with the Hong Kong bourse.

CRB-701, which recently completed enrollment in the dose escalation part of its Phase I clinical trial, is meant to treat relapsed or refractory metastatic cervical cancer, the filing said.